Proteomic Biomarker

The ibiomic product is a new blood test to a disease of interest.

Knowing the formula developed by us you can run multiple blood tests providing reliable diagnostics.

How we develop the test:

Single-protein measurements are limited

Individual proteins frequently differ on average between healthy and diseased populations. However, because biological variability is high, the distributions of protein levels often overlap substantially, limiting the diagnostic power of any single biomarker.

Figure 1. Each protein shows different average levels in healthy and diseased groups, but substantial overlap limits its diagnostic reliability when used alone.

Structure emerges in multi-protein space

When proteins are analyzed together, patients can be represented as points in a multi-dimensional protein-expression space. Using special algorithms we can select pairs of proteins. Biological structure begins to emerge in the 2-protein space: healthy and diseased samples occupy distinct regions.

Figure 2: When two proteins are considered together, patients occupy structured regions in protein-expression space, enabling clearer separation between healthy and diseased samples.

In this representation, separation between groups becomes possible, although some samples remain ambiguous or misclassified due to biological heterogeneity and measurement noise.

Compact multi-protein biomarkers improve discrimination

Further progression of our approach leads to even better sample separation in protein space. It is important to stay low-dimensional to avoid overfitting.

Figure 3. 3-protein space in this case is better for effective diagnostics.

Interpretability

ibiomic provides biomarker formula for diagnostics that is interpretable: you can easily see which proteins are increased and which are dicreased in disease. This makes the ibiomic biomarker formula explainable, and helps in FDA-approval and in search for treatments.

Page updated

Google Sites

Report abuse